Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypert...
J&J's TECVAYLI® Achieves Breakthrough 100% Response Rate in Multiple Myeloma Clinical Trials
Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data showing 100% MRD negativity in newly diagnosed multiple myeloma patients treated with MajesTEC-5 induction and MajesTEC-4 maintenance therapies, presented at the 2024 ASH Annual Meeting.
Related Clinical Trials:
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for ...
Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data showing 100% MRD negativity in newly diagnosed multiple myeloma patients treated with MajesTEC-5 induction and MajesTEC-4 maintenance therapies, presented at the 2024 ASH Annual Meeting.
Related Clinical Trials:
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction
DARZALEX FASPRO significantly delayed progression from high-risk SMM to active MM and extended overall survival in Phase 3 AQUILA study, presented at 2024 ASH Annual Meeting.
DARZALEX® (daratumumab) subcutaneous formulation shows 51
DARZALEX® (daratumumab) SC significantly delayed progression from high-risk smouldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival in the Phase 3 AQUILA study, compared to active monitoring. The study showed potential to prevent end-organ damage and extend progression-free survival.
DARZALEX FASPRO Shows Breakthrough 51% Risk Reduction in Multiple Myeloma Trial
DARZALEX FASPRO® significantly delayed progression from high-risk SMM to active MM and extended overall survival in the Phase 3 AQUILA study, compared to active monitoring.
Liquid Handling System Market Size to Hit US$ 6.95 Billion by 2032, Owing to Rising ...
The Liquid Handling System Market, valued at USD 4.20 billion in 2023, is projected to reach USD 6.95 billion by 2032, growing at a CAGR of 5.77%. This growth is driven by automation in drug discovery, genomics, and clinical applications, supported by technological advancements and increased demand for precision medicine.
Toxoplasmosis Treatment Drugs Market Size, Growth Demand And Share Analysis 2033
The toxoplasmosis treatment drugs market is projected to grow from $3.16 billion in 2023 to $4.18 billion by 2028, driven by rising prevalence, product innovations, and increased healthcare expenditure.
The Weekly Roundup: December 2-6
Dermatology news includes cacao's skin rejuvenation potential, regenerative medicine for vitiligo, delgocitinib's skin barrier restoration, and comparing risankizumab and deucravacitinib in psoriasis. Also, AI diagnoses onychomycosis, and integrating dermatologists into primary care improves diagnostics and cost-effectiveness.
© Copyright 2024. All Rights Reserved by MedPath